1-9 of 9
Ulka Vaishampayan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, III, Kobe C. Yuen, Asim Datye, Andrew J. Armstrong, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4746–4756.
https://doi.org/10.1158/1078-0432.CCR-21-0063
Published: 01 September 2021
View article titled, A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5598–5608.
https://doi.org/10.1158/1078-0432.CCR-20-1408
Published: 02 November 2020
View article titled, Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Open the PDF for Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View article titled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

Himisha Beltran, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, Andrew J. Armstrong, Mark Stein, Jacek Pinski, Juan M. Mosquera, Verena Sailer, Rohan Bareja, Alessandro Romanel, Naveen Gumpeni, Andrea Sboner, Etienne Dardenne, Loredana Puca, Davide Prandi, Mark A. Rubin, Howard I. Scher, David S. Rickman, Francesca Demichelis, David M. Nanus, Karla V. Ballman, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-18-1912
Published: 03 January 2019
View article titled, A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Open the PDF for A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers in another window
Includes: Supplementary data
Journal Articles

Advantages and Adversities of the Weighted Toxicity Score

Ulka Vaishampayan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 4918–4920.
https://doi.org/10.1158/1078-0432.CCR-18-1562
Published: 15 October 2018
View article titled, Advantages and Adversities of the Weighted Toxicity Score
Open the PDF for Advantages and Adversities of the Weighted Toxicity Score in another window
Journal Articles

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Elisabeth I. Heath, David W. Hillman, Ulka Vaishampayan, Shijie Sheng, Fazlul Sarkar, Felicity Harper, Melvin Gaskins, Henry C. Pitot, Winston Tan, S. Percy Ivy, Roberto Pili, Michael A. Carducci, Charles Erlichman, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7940–7946.
https://doi.org/10.1158/1078-0432.CCR-08-0221
Published: 01 December 2008
View article titled, A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Open the PDF for A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer in another window
Journal Articles

Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon α

Ulka Vaishampayan, Judith Abrams, Denise Darrah, Vicky Jones, Malcolm S. Mitchell
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3696–3701.
Published: 01 December 2002
View article titled, Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon α
Open the PDF for Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon α in another window
Journal Articles

Her-2/ neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors

Rafael E. Jimenez, Maha Hussain, Fernando J. Bianco, Jr., Ulka Vaishampayan, Pam Tabazcka, Wael A. Sakr, J. Edson Pontes, David P. Wood, Jr., David J. Grignon
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2440–2447.
Published: 01 August 2001
View article titled, Her-2/ <em>neu</em> Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: <subtitle>Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors</subtitle>
Open the PDF for Her-2/ <em>neu</em> Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: <subtitle>Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors</subtitle> in another window